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Abstract
Background. Measurements of glycated hemoglobin (HbA1c) in non-diabetics can identify subjects who are 
at increased risk for future cardiovascular (CV) events. There is no consensus agreement whether the addition 
of HbA1c improves the CV risk prediction.
Objectives. The objective of this study was to assess mean values of HbA1c levels in a representative sample 
of general, diabetes mellitus (DM)-free Polish population, and its subgroups, and to identify important 
covariants.
Material and methods. HbA1c was measured in blood samples collected from 1,868 participants (males/
females (M/F) 901/967, age: range 18–74, mean 44.03 years) of NATPOLL 2011 study without previously 
and newly diagnosed DM. Univariate and multivariate analyses of HbA1c level in relationship to age, body mass 
index (BMI), waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting 
plasma glucose (FPG), lipids, creatinine, C-reactive protein (CRP), gender, and smoking status were performed.
Results. Mean HbA1c level was 5.46 ±0.31% in the entire population and significantly higher levels were 
found in subjects with male gender, hypertension, fasting hyperglycemia, abdominal obesity, and higher 
BMI values but not in smokers. Univariate analysis revealed numerous significant correlations of HbA1c with 
the highest values correlation coefficient values for age (r = 0.55), FPG (r = 0.43), WC (r = 0.36), and BMI 
(r = 0.36). The best, final multivariate model explained 40% of HbA1c variance and the most important 
covariant was the age, explaining approx. 50% of R2, followed by FPG and BMI.
Conclusions. HbA1c in non-diabetic level is associated with certain CV risk factors, mainly with age. Since 
known risk factors explain less than a half of HbA1c variance, the inclusion of HbA1c into the assessment may 
increase the performance of algorithms predicting CV risk.
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According to different algorithms for cardiovascular 
(CV) risk, type 2 diabetes mellitus (DM2) is considered 
an equivalent of coronary heart disease (CHD). Also, pa-
tients with diabetes, when compared to non-diabetic sub-
jects, have a higher prevalence of CHD, a greater extent 
of coronary ischemia, and are more likely to have a myo-
cardial infarction (MI) and silent myocardial ischemia. 
In the general population, there is even a larger group 
of subjects who do not meet the diagnostic criteria for dia-
betes but are affected by different degrees of dysglycemia, 
including impaired fasting glucose or impaired glucose 
tolerance. Measurements of glycated hemoglobin (HbA1c) 
can identify subjects who are at increased risk not only 
for  the  future development of DM2,1,2 but also for CV 
events.3–6 
In a meta-analysis, HbA1c was found to be the best mark-
er of dysglycemia and CV risk in subjects without DM2.7 
In  the  INTERHEART study, the  association between 
HbA1c and the history of MI was stronger in non-diabet-
ics than in patients with DM2.8 Mechanisms underlying 
this association remain unclear and there is no consensus 
agreement whether addition of HbA1c level as a diagnos-
tic tool improves the risk prediction for cardiovascular 
disease (CVD).9 
Material and methods 
A detailed design of the NATPOL 2011 Survey has been 
reported elsewhere.10 Briefly, the NATPOL 2011 survey was 
designed as a cross-sectional representative observational 
study to assess the prevalence of main atherosclerotic CVD 
risk factors in Poland. It was carried out on a representative 
sample of Polish residents aged 18–79 years. The partici-
pants were randomly selected in bundles, in a stratified, 
proportional draw performed in 3 stages. The response 
rate among respondents who were invited and eligible 
for the study was equal to 66.4%. Finally, 2,413 subjects 
(1,245 females and 1,168 males) participated in the survey. 
Subjects with previously diagnosed diabetes, with HbA1c 
level >6.5 % and incomplete biochemical measurements 
were excluded from the current analysis. Therefore, the fi-
nal analysis was performed in n = 1,868 subjects (male/
female 901/967, mean age 44.03 ±16.28 years) and the com-
parisons between the subgroups with and without the fol-
lowing: hypertension, fasting hyperglycaemia, abdominal 
obesity and according to body mass index (BMI) and cur-
rent smoking status were performed.
The Institutional Ethics Committee at the Medical Uni-
versity in Gdańsk (Poland) approved the study protocol; all 
participants provided written informed consent. 
The examination was performed by 234 well-trained 
nurses who lived in or close to  the  randomly selected 
geographical bundles. Participants were examined dur-
ing 2 visits at subjects’ homes. The examination of an in-
dividual subject comprised the  following components: 
completing the questionnaire, taking blood pressure read-
ings and anthropometric measurements (weight, height, 
waist circumference (WC)), and collecting blood and urine 
samples. 
The questionnaire was completed during the 1st  visit. Only 
selected items of the questionnaire were used for the follow-
ing substudy including age, history of diabetes and hyper-
tension, antihypertensive and statin use, and smoking.
Blood pressure readings were taken 3 times during the 1st 
and the 2nd visit using fully automated oscillometric blood 
pressure measuring device (A&D UA 767 A&D Company, 
Tokyo, Japan). Mean values of 2nd and 3rd measurements 
from 2 visits were used for the analysis. Hypertension was 
diagnosed if during both visits mean systolic blood pres-
sure (SBP) was ≥140 mm Hg and/or mean diastolic blood 
pressure (DBP) was ≥90 mm Hg or if the patient was taking 
hypertensive drugs over the past 2 weeks due to an earlier 
diagnosis of hypertension.
Anthropometric measurements used in the following 
substudy included weight, height and WC. Weight was 
measured with the subject shoeless and dressed in light 
clothes (without outer garments – jackets, coats, etc.), us-
ing approved personal electronic scales, with accuracy 
to the nearest 0.1 kg. Height was measured using a portable 
personal measuring device with accuracy to the nearest 
centimeter, and WC using a tailor’s tape measure, with 
an accuracy to the nearest 0.5 cm. Overweight was defined 
as BMI 25.0–29.9 kg/m2, obesity as BMI ≥30 kg/m2 and 
abdominal obesity as WC ≥102 cm in men and WC ≥ 88 cm 
in women. 
Blood and  urine samples were taken from subjects 
at the 2nd visit, after 10. to 12-hour fasting. Frozen plasma 
and serum samples were transported to the central labora-
tory, where blood and urine analyses were carried out. 
Routine blood tests: fasting plasma glucose (FPG), to-
tal cholesterol (TC), high-density lipoprotein cholesterol 
(HDL-C), serum triglycerides (TG), plasma creatinine, se-
rum C-reactive protein (CRP), and urine albumin and cre-
atinine were measured on the Architect c8000 chemistry 
analyzer (Abbott Laboratories, Chicago, USA). Glucose 
was measured using the hexokinase method. Serum cho-
lesterol was measured with the enzymatic method, using 
cholesterol esterase and cholesterol oxidase; serum HDL-C 
was measured with the direct method using Accelerator 
Selective Detergent (Abbott Laboratories, Chicago, USA) 
with accelerated non-HDL-C oxidation and HDL-C dis-
solving. Serum triglycerides were measured by the enzy-
matic method using glycerol kinase and glycerol phosphate 
oxidase. Low-density lipoprotein cholesterol (LDL-C) was 
calculated using Friedewald formula. If TG concentration 
was >350 mg/dL, the Friedewald formula was not used. 
Hypercholesterolemia was defined as TC ≥190 mg/dL 
(4.9 mmol/L) or taking statins. Fasting hypergylcemia was 
defined as fasting glucose ≥100 mg/dL (≥5.6 mmol/L). Plas-
ma creatinine was measured using Jaffe method, method 
and CRP in serum using immunoturbidimetric method. 
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Serum insulin was measured on the Architect i2000sr, 
immunochemistry analyzer (Abbott Laboratories) us-
ing chemiluminescence immunoassay. Urine albumin 
was measured by the immunoturbidimetric method and 
creatinine using the Jaffe method. Albumin–creatinine 
ratio (ACR) was calculated on the basis of urine albumin 
and urine creatinine measurement.
HbA1c level was measured in ethylenediaminetetraace-
tic acid (EDTA) whole blood samples using turbidimetric 
inhibition immunoassay on the Cobas Integra 800 analyzer 
(Roche Diagnostics, Mannheim, Germany). The statistical 
analysis of the data was performed using R package v. 3.0.2 
(The R Foundation, Vienna, Austria). 
We compared mean values of HbA1c in both genders, 
in subjects with and without the following: hypertension, 
impaired fasting glucose and  current smoking status. 
Due to the skewness, ACR values were log-transformed. 
We  used the  student’s t-test or  analysis of variance 
(ANOVA) and χ2 test, where appropriate. All results were 
presented as means ± standard deviation (SD). Significant 
p-value was set at p < 0.05.
We performed univariate analysis calculating correla-
tion coefficients of HbA1c with the following quantitative 
parameters: age, BMI, WC, SBP, DBP, FPG, insulin, lipids, 
creatinine, CRP, and ACR using Pearson’s method.
For the multivariate analysis, we included all quantitative 
parameters mentioned above, and additionally gender and 
smoking habit, removing variables that highly correlated 
with the others (r > 0.6) namely DBP, WC and LDL-C. 
The selection of variables for the final model was per-
formed using “leaps” R package applying all subsets regres-
sion method. We calculated standardized beta coefficients 
“QuantPsyc” R  package) together with corresponding 
significance and R2 for all variables selected for the final 
model using the “relaimpo” R package with “lmg”, “last”, 
“first”, and “Pratt” algorithms. 
Table 1. Characteristics of all participants and men vs women
Parameter
All subjects Men Women
p-value
mean ±SD or n [%] mean ±SD or n [%] mean ±SD or n [%] 
Number of patients 1868 901 (48.2) 967 (51.8) –
Age [years] 44.03 ±16.28 43.34 ±15.66 44.69 ±16.82 0.0725
BMI [kg/m2] 26.2 ±4.8 26.9 ±4.5 25.5 ±5.0 <0.0001
Normal/low BMI 810 (43.4) 303 (33.6) 507 (52.4) <0.0001
Overweight 687 (36.8) 394 (43.7) 293 (30.3) <0.0001
Obesity 371 (19.9) 204 (22.6) 167 (17.3) <0.0001
WC [cm] 90.35 ±13.92 96.5 ±12.22 84.62 ±12.93 <0.0001
Abdominal obesity, n 1104 (59.1) 537 (59.6) 567 (58.6) 0.7062
SBP [mm Hg] 127.1 ±17.8 131.5 ±16.6 123.1 ±17.9 <0.0001
DBP [mm Hg] 79.8 ±9.9 80.9 ±10.3 78.8 ±9.5 <0.0001
Hypertension, n 551 (29.5) 299 (33.2) 252 (26.1) <0.0001
Glucose [mg/dL] 90.69 ±11.81 92.83 ±11.94 88.69 ±11.33 <0.0001
Glucose [mmol/L] 5.04 ±0.66 5.16 ±0.66 4.93 ±0.63 <0.0001
Insulin [mLU/L] 8.25 ±5.44 8.49 ±6.24 8.03 ±4.55 0.0761
HbA1c [%] 5.46 ±0.31 5.47 ±0.31 5.44 ±0.31 0.0280
HbA1c [mmol/mol] 36.2 ±3.4 36.3 ±3.4 35.0 ±3.4 0.0280
Hyperglycemia, n 368 (19.7) 232 (25.7) 136 (14.1) <0.0001
TC [mg/dL] 199.9 ±41.3 198.7 ±42.4 200.9 ±40.15 0.2425
LDL-C [mg/dL] 125.9 ±34.4 125.9 ±34.7 125.9 ±34.12 0.9699
HDL-C [mg/dL] 50.3 ±13.1 46.0 ±12.6 54.3 ±12.35 <0.0001
TG [mg/dL] 120.4 ±80.8 138.2 ±99.5 103.8 ±53.24 <0.0001
CRP [mg/dL] 2.77 ±5.63 3.02 ±7.05 2.54 ±3.86 0.0735
Plasma creatinine [mg/dL] 0.82 ±0.17 0.9 ±0.15 0.75 ±0.15 <0.0001
ACR [mg/g] 15.67 ±187.88 12.74 ±65.39 18.39 ±253.42 0.5028
logACR [mg/g] 0.78 ±0.35 0.72 ±0.36 0.84 ±0.33 <0.0001
Current smoking, n 516 (27.6) 281 (31.2) 235 (24.3) 0.0011
BMI – body mass index; SBP – mean systolic blood pressure; DBP – mean diastolic blood pressure; TC – total cholesterol; LDL-C – low-density lipoprotein 
cholesterol; HDL-C – high-density lipoprotein cholesterol; TG – triglycerides; ACR – albumin/creatinine ratio; WC – waist circumference; CRP – C-reactive 
protein; SD – standard deviation.
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Results
Characteristics of the population studied are present-
ed in Table 1. Mean HbA1c level value was 5.46 ±0.31% 
(36.2  ±3.4 mmol/mol) and  was significantly higher 
in men than in women (Table 1). HbA1c level was higher 
in subjects with hypertension 5.61 ±0.31% vs 5.39 ±0.29% 
(37.8 ±3.4 mmol/mol vs 35.4 ±3.2 mmol/mol, p < 0.001) than 
without; higher in fasting hyperglycemia – 5.69 ±0.32% 
(38.7 ±3.5 mmol/mol) than in subjects with normal fasting 
glucose – 5.40 ±0.28% (35.5 ±3.1 mmol/mol, p < 0.001); 
and higher in subjects with abdominal obesity than with-
out – 5.54 ±0.31% vs 5.34 ±0.27% (37.1 ±3.4 mmol/mol vs 
34.9 ±3.0 mmol/mol, p < 0.001). Significant differences 
in  HbA1c were observed in  subjects with normal/low 
BMI, overweight and obesity: 5.34 ±0.26% vs 5.50 ±0.30% 
vs 5.62 ±0.31%, respectively (34.9 ±2.8 mmol/mol vs 36.6 
±3.3 mmol/mol vs 37.9 3.4 mmol/mol, p < 0.001). No sig-
nificant difference in HbA1c was observed in smokers vs 
non-smokers.
Univariate analysis revealed numerous significant cor-
relations of HbA1c with other covariants including age 
(r = 0.55) (Fig. 1), fasting glucose (r = 0.43), WC (r = 0.36), 
BMI (r = 0.36), SBP (r = 0.28), LDL-C (r = 0.26), total choles-
terol (r = 0.23), and DBP (r = 0.21). Correlation coefficients 
for insulin, creatinine, ACR, triglycerides, and HDL-C, 
although significant, were below 0.2.
The best final multivariate linear regression model was 
selected with all subsets regression procedures and in-
cluded following variables independently associated with 
HbA1c levels: age, FPG, BMI, TC, HDL-C, ACR, TG, and 
gender (Table 2). Albumin–creatinine ratio and gender 
were not significant correlates. The final model explained 
40.25% of HbA1c variance. The most important covari-
ant of HbA1c, irrespective of the method of assessment 
of the relative importance of variables selected to the fi-
nal model, was age, followed by FPG and, in the majority 
of methods, BMI (Fig. 2). Relative R2 for the other covari-
ants was negligible, below 10%.
Discussion
Our study revealed that the mean HbA1c level in a rep-
resentative sample of the Polish population without pre-
viously diagnosed diabetes and with non-diabetic range 
of HbA1c was similar to other non-diabetic population 
studies.6,11 HbA1c levels were higher in subjects with cer-
tain well-known CV risk factors, namely male gender, 
obesity, abdominal obesity, hypertension, and hypercho-
lesterolemia but not in current smokers. 
Univariate analysis revealed numerous significant cor-
relations with other covariants, with highest r values found 
for age and also for FPG, WC and BMI. It should be noted 
that the correlation between FPG and HbA1c was not very 
high and similar to that found in the Dutch general popula-
tion.12 In the large Finnish METSIM study, the respective 
r coefficient in non-diabetic men was even lower – 0.207. 
On the other hand, our analysis, when compared with 
METSIM study, revealed a 2-fold higher r coefficients 
for HbA1c levels and age, BMI and SBP.11 
In our study, age, glucose, BMI, total cholesterol, HDL-C, 
and TG were significant and independent determinants 
of HbA1c level. In contrast to other studies, other covari-
ants including CRP11 and smoking6 were not included into 
the model. The main determinant of HbA1c variance in our 
participants was age, which explained half of the variance 
of HbA1c in the model, similarly to the METISM study. 
The relative R2 determined by FPG was approx. 25%, as re-
ported in METSIM study (24.7%).11 
In METSIM study, age, FPG, CRP, genetic risk score, 
and  smoking were the  most important determinants 
of the variance in HbA1c among participants without DM2, 
explaining 12–14% of variance in HbA1c, whereas insulin 
secretion and insulin sensitivity indices explained only <2% 
of variance.11 In a Dutch study performed in non-diabetic 
Table 2. Multivariate associations between HbA1c and clinical/
biochemical parameters in the final model expressed  
as adjusted beta coefficients
Parameter beta p-value 
Age 0.40 <0.001
Gender −0.02 ns
FPG 0.26 <0.001
BMI 0.09 <0.001
TC 0.10 <0.001
HDL-C −0.13 <0.001
TG −0.05 <0.05
logACR 0.02 ns
FPG – fasting plasma glucose; BMI – body mass index; TC – total 
cholesterol; HDL-C – HDL cholesterol; TG – triglycerides; ACR – albumin/
creatinine ratio; ns – not significant; significant p-value <0.05.
Fig. 1. Correlation between HbA1c and age
correlation between HbA1c and age
age [years]
H
bA
1c
 [%
]
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Fig. 2. Relative importance for HbA1c expressed as % of R2 for the final model calculated using different methods 
adults, regression model that included age, gender, BMI, 
mean corpuscular hemoglobin, mean corpuscular hemo-
globin concentration, current smoking, and alcohol con-
sumption explained only 26% of HbA1c variance.6 
Our model predicted HbA1c levels more precisely, 
explaining 40% of  the  variance of  HbA1c compared 
with 14–26% of the variance in other studies.6,11 Differ-
ences between our and other studies may be explained 
by the lower mean age of our subjects, resulting in lower 
incidence of concomitant CV risk. Other studies have 
shown that variability in HbA1c may be contributed to age, 
ethnicity, smoking, anemia, and genetic factors.13–16 Apart 
from age and, to a minor extent FPG and BMI, the influ-
ence of other variables in our model was small, almost 
negligible. 
Of note, multivariate regression models including tra-
ditional and non-traditional risk factors/markers explain 
only 40% of variance of HbA1c. Therefore, the physiological 
link between HbA1c and CV risk in non-diabetic subjects 
remains unexplained, thus suggesting that HbA1c may 
be an independent CV risk factor. Prediabetes is a well-
known CV risk factor and HbA1c should be considered 
a useful independent CV risk factor also in the diabetes-
free population. 
The studies on the possible determinants of HbA1c levels 
in non-diabetic populations are difficult to compare due 
to methodological differences, including diagnosis of dia-
betes, selection of the potential covariates and statistical 
methodology. 
Several limitations of our study must be mentioned. 
We did not perform oral glucose tolerance test (OGTT) 
and  the  participants had only 1 FPG measurements; 
therefore, to minimize the possibility of including patients 
with DM to the analysis, we excluded the participants with 
HbA1c ≥ 6.5% as in other studies.17 However, post-load 
glucose measurement did not improve the  prediction 
of HbA1c.11
Conclusions
HbA1c in non-diabetic level is associated with some CV 
risk factors, mainly with age. Since known risk factors ex-
plain less than half of its variance, the inclusion of HbA1c 
into risk assessment may increase the performance of al-
gorithms predicting CV risk.
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